Introduction Pain management is one of the most important aspects of treating combat injuries. Current techniques involve systemic analgesia, which has consequences for the patient and for the hospital. Optimal analgesia often results in an obtunded patient, unable to operate a weapon. A widely used veterinarian product contains Lidocaine, Bupivacaine, Adrenaline and Cetrimide. We are working on bringing this spray-on product to the human world. This study is the first in man trial, looking at safety and efficacy. Methodology 24 adults with small-to-medium lacerations of the limbs were treated with in four cohorts with Medi-Solfen (MS) prior to suturing. Cohort 1 had MS applied without a cover. Cohort 2 had an occlusive cover applied and left for 5 minutes. Cohort 3 were left for 10 minutes and Cohort 4 for 15 minutes. Blood levels were taken for toxicology and pain scores were assessed. For suturing, 'rescue' analgesia with injectable LA was available if required. Results None of the cases treated with an occlusive cover (Cohorts 2-4) required rescue analgesia and had pain scores between 0 and 2. One patient in Cohort 1 required rescue analgesia. Three were no significant changes in blood pressure, ECG, heart rate or respiratory rate. There were no neurological symptoms. Blood lidocaine levels peaked at 5 nanograms/ml (toxicity not normally described until 6 micrograms/ml). Bupivacaine levels peaked at 10.8 nanograms/ml (toxicity not normally described until 2 micrograms/ml). Conclusion The application of MS with an occlusive cover offers sufficient analgesia after 5 minutes to allow suturing of small-to-medium lacerations in adults. We are looking to bring this technology onto the battlefield. Perhaps this product could be available to every soldier in their first aid kit.